Arun Singh, MD, Medical Oncologist at UCLA, describes the advantages of mouse models. Certis provides Orthotopic PDX (Patient-Derived Xenograft) mouse models for cancer patients.
Fritz Eilber, MD, UCLA Surgery Division of Oncology discusses why he joined the Board of Directors at Certis Oncology. Certis provides Orthotopic PDX (Patient-Derived Xenograft) mouse models for cancer patients.
CERTIS ONCOLOGY COLLABORATES WITH SCIENCE EXCHANGE TO OFFER ON-DEMAND ACCESS TO ITS ORTHOTOPIC PDX SERVICES SAN DIEGO, OCTOBER 25, 2018. Science Exchange, the leading marketplace for outsourced R&D, and Certis Oncology, a leading provider for preclinical mouse modeling and tumor banking services, announced they are working together to bring Certis’ breakthrough orthotopic PDX-based CRO services to the global research community
By: Marisa Keller Orthotopic Patient-Derived Xenografts (PDX) Despite the rise of personalized approaches to the treatment of cancer, translating these therapies into a clinical setting still poses an exceptional challenge. This is highlighted in drug development where research into targeted therapies requires highly characterized tools that mimic human tumors as closely as possible. Patient-derived Xenografts (PDXs) are one such tool
CERTIS ONCOLOGY PARTNERS WITH REVEAL BIOSCIENCES TO OFFER ADVANCED PRE-CLINICAL ONCOLOGY SERVICES SAN DIEGO, AUGUST 13, 2018. Certis Oncology Solutions and Reveal Biosciences today announced a strategic partnership in which the two companies will collaborate to provide an innovative, next-generation suite of pre-clinical oncology services. Under the agreement, Reveal will leverage its Artificial Intelligence (AI)-based pathology tools to generate advanced
You can now access the Certis Oncology profile and request our orthotopic PDX pre-clinical services at https://www.scientist.com/researchers/. Our research team is looking forward to working with you!
CERTIS ONCOLOGY ANNOUNCES CLIA CERTIFICATION FOR HIGH-COMPLEXITY TESTING The Company has designed Laboratory Developed Tests for its innovative orthotopic PDX mouse modeling techniques to determine the best treatment options for cancer patients. SAN DIEGO, JULY 16, 2018. Certis Oncology Solutions, Inc., a new precision medicine company focused on individualized patient care, today announced that it has received its CLIA Certificate
Thank you to La Jolla Playhouse for a fantastic Innovation Night! Peter Ellman (CEO) and Jonathan Nakashima, PhD (Director of Operations) and the rest of our team enjoyed meeting everyone!
Dr. Arun Singh, a Stand up to Cancer researcher and UCLA doctor, joins the panel to share how people can get involved. “Go to getscreenednow.org and take a quick survey to find out which cancer screening tests may be right for you. Take the pledge and make an appointment to speak with your physician about cancer screening recommendations which can
Fritz Eilber, MD and Arun Singh, MD chat with UCLA oncology patient Rachel Young Huff about precision medicine opportunities for patients with in vivo mouse models.